TIDMABC
RNS Number : 1970G
ABCAM PLC
11 November 2022
ABCAM PLC
Result of General Meeting - Shareholders approve AIM
Delisting
11 November 2022, Cambridge, UK - Abcam plc (AIM: ABC; Nasdaq:
ABCM) ("Abcam" or the "Company"), a global leader in the supply of
life science research tools, today announces that the resolution
put to its General Meeting held today for the cancellation of the
admission of its Ordinary Shares to trading on AIM was passed.
The votes were as follows:
Special Resolution In Favour % In Against % Against % of Withheld
Favour ISC voted
Approve the cancellation
of the admission
to trading on AIM
of the ordinary shares
of nominal value
0.2p each in the
capital of the Company
and authorise the
directors of the
Company to take all
action reasonable
or necessary to effect
1. such cancellation 189,580,480 98.19% 3,485,254 1.81% 84.29 60,213
------------------------- ------------ -------- ---------- ---------- ----------- ---------
The issued share capital ("ISC") as of the date of the meeting
was 229,059,401 Ordinary Shares.
The percentage of voting shares in favour and against is the
percentage of shares voted and exclude shares on which votes were
withheld.
The Company will continue to provide shareholders with an
opportunity to deposit their Ordinary Shares with the Depositary in
exchange for delivery of ADSs, without cost, in connection with the
AIM Delisting prior to or on 14 December 2022 (being the date on
which the AIM Delisting takes effect). Further details are set out
in the Shareholder Circular dated 17 October 2022, available at
https://corporate.abcam.com/investors/aim-delisting/
The Company confirms that, as at today's date, the pending
timetable for the cancellation of the admission to trading on AIM
of the Company's ordinary shares is as follows:
PENDING TIMETABLE
Last date for receipt by the Registrar
from certificated shareholders of 5.00 p.m. on 1 December 2022
duly completed Certificated Transfer
Forms and original share certificates
Latest date for receipt by the Depositary
from CREST holders of duly completed 5.00 p.m. on 1 December 2022
issuance forms
Expected date for issuance of ADSs 12 December 2022
to block transfer participants
Expected date of mailing of ADS confirmations 13 December 2022
to shareholders by the Depositary
Last day of dealings in the Ordinary
Shares on AIM 13 December 2022
Cancellation of admission to trading
on AIM of the Ordinary Shares 7.00 a.m. on 14 December 2022
_______
Notes to the timetable
(1) References to times and dates in this announcement are to
times and dates in London, United Kingdom, unless otherwise
stated.
(2) Each of the times and dates in the above timetable are
subject to change. If any of the above times and/or dates change,
the revised times and/or dates will be notified to shareholders by
announcement through a Regulatory Information Service.
The capitalised terms used in this announcement have the meaning
set out in the announcement made by the Company at 7.00 a.m. on 17
October 2022.
For further information, please contact:
Abcam + 44 (0) 1223 696 000
Marc Perkins, Company Secretary
Tommy J. Thomas, CPA, Vice President, Investor Relations +1 617 577 4205
Numis - Nominated Advisor & Joint Corporate Broker + 44 (0) 20 7260 1000
Freddie Barnfield / Duncan Monteith
Morgan Stanley - Joint Corporate Broker + 44 (0) 207 425 8000
Tom Perry / Luka Kezic
FTI Consulting + 44 (0) 20 3727 1000
Ben Atwell / Lydia Jenkins / Julia Bradshaw
About Abcam plc
As an innovator in reagents and tools, Abcam's purpose is to
serve life science researchers globally to achieve their mission
faster. Providing the research and clinical communities with tools
and scientific support, the Company offers highly validated
antibodies, assays and other research tools to address important
targets in critical biological pathways.
Already a pioneer in data sharing and ecommerce in the life
sciences, Abcam's ambition is to be the most influential company in
life sciences by helping advance global understanding of biology
and causes of disease, which, in turn, will drive new treatments
and improved health.
Abcam's worldwide customer base of approximately 750,000 life
science researchers uses Abcam's antibodies, reagents, biomarkers
and assays. By actively listening to and collaborating with these
researchers, the Company continuously advances its portfolio to
address their needs. A transparent program of customer reviews and
datasheets, combined with industry-leading validation initiatives,
gives researchers increased confidence in their results.
Founded in 1998 and headquartered in Cambridge, UK, the Company
has served customers in more than 130 countries. Abcam's ordinary
shares are listed on the London Stock Exchange (AIM: ABC) and its
American Depositary Shares (ADSs) trade on the Nasdaq Global Market
(Nasdaq: ABCM).
For more information, please visit www.abcam.com or
www.abcamplc.com
Forward-Looking Statements
This announcement contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Any express or implied statements contained in this announcement
that are not statements of historical fact may be deemed to be
forward-looking statements, including, without limitation,
statements regarding Abcam's portfolio and ambitions, expectations
surrounding the timing of the AIM Delisting, as well as statements
that include the words "expect," "intend," "plan," "believe,"
"project," "forecast," "estimate," "may, " "should," "anticipate"
and similar statements of a future or forward-looking nature.
Forward-looking statements are neither promises nor guarantees, but
involve known and unknown risks and uncertainties that could cause
actual results to differ materially from those projected,
including, without limitation, the important factors discussed
under the caption "Risk Factors" in Abcam's Annual Report on Form
20-F for the year ended 31 December 2021, which is on file with the
SEC and is available on the SEC website at www.sec.gov, as such
factors may be updated from time to time in Abcam's other filings
with the SEC. Any forward-looking statements contained in this
announcement speak only as of the date hereof and accordingly undue
reliance should not be placed on such statements. Abcam disclaims
any obligation or undertaking to update or revise any
forward-looking statements contained in this announcement, whether
as a result of new information, future events or otherwise, other
than to the extent required by applicable law.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ROMFLFESLFLLLIF
(END) Dow Jones Newswires
November 11, 2022 10:30 ET (15:30 GMT)
Abcam (LSE:ABC)
Historical Stock Chart
From Nov 2024 to Dec 2024
Abcam (LSE:ABC)
Historical Stock Chart
From Dec 2023 to Dec 2024
